Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

January 31, 2008

Study Completion Date

September 30, 2009

Conditions
GlioblastomaAstrocytomaPineoblastomaRhabdoid TumorSupratentorial Neoplasms
Interventions
PROCEDURE

Stem Cell Transplant

"Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."

Trial Locations (1)

60614

Children's Memorial Hospital, Chicago

All Listed Sponsors
lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

NCT00179803 - Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | Biotech Hunter | Biotech Hunter